Eosinophilic granulomatosis with polyangiitis is a rare immune-related condition that involves the respiratory system and blood vessels. Managing this complex disease requires a tailored approach that combines controlling inflammation, protecting vital organs, and maintaining quality of life. Advances in understanding how the condition develops have opened doors to both proven treatments and promising therapies currently being explored in research settings.

Navigating Treatment: What People with EGPA Need to Know

Eosinophilic granulomatosis with polyangiitis, or EGPA, is a condition that calls for careful medical attention and a treatment plan designed around each person’s unique situation. The main goals when treating EGPA are to calm down the body’s overactive immune system, reduce the damaging inflammation in blood vessels and tissues, prevent complications that can affect the heart, kidneys, nerves, or other organs, and help people return to their normal activities as much as possible. The condition tends to develop in stages over time, often starting with respiratory symptoms like asthma or sinus problems before progressing to affect other parts of the body.^[1]

Because EGPA can present differently from one person to another, treatment decisions depend heavily on how severe the disease is and which organs are involved. Doctors typically classify patients into categories based on risk factors to determine the intensity of treatment needed. Someone with milder disease confined mainly to the lungs and sinuses might need a less aggressive approach than someone whose condition has affected the kidneys, heart, or nervous system.^[9]

There are well-established treatments that medical societies around the world recommend for EGPA, based on decades of experience and research. At the same time, scientists are actively investigating new therapies in clinical trials, which are carefully controlled research studies where patients can access experimental treatments that might become standard care in the future. Understanding both the proven approaches and the emerging options helps people with EGPA and their families make informed decisions about their care.

Standard Treatments That Form the Foundation of Care

The cornerstone of EGPA treatment is a group of medications called corticosteroids, which are powerful drugs that reduce inflammation throughout the body. The most commonly used corticosteroid is prednisone, though doctors may also prescribe methylprednisolone, especially when given through a vein in more urgent situations. These medications work by dampening the immune system’s activity, which in turn reduces the number of eosinophils (a type of white blood cell that causes tissue damage in EGPA) and calms the inflammation in blood vessels.^[10]

When someone is first diagnosed with EGPA, doctors typically start with a high dose of prednisone, usually around 1 milligram per kilogram of body weight per day, up to a maximum of 60 milligrams daily. This initial high dose is maintained for about two to three weeks to quickly bring the disease under control. After this initial period, the dose is gradually reduced over many months. The goal is to find the lowest dose that keeps the disease quiet while minimizing side effects. A typical tapering schedule might aim for 20 milligrams per day by three months, 10 milligrams per day by six months, and 5 milligrams per day by one year, though individual timelines vary.^[10][14]

For people with more severe EGPA, particularly those with life-threatening organ involvement such as kidney inflammation, heart problems, or extensive nerve damage, corticosteroids alone are not enough. In these situations, doctors add other immunosuppressive medications that further calm the immune system. The choice of additional medication depends on the severity of disease and which organs are affected.^[9]

Cyclophosphamide is one of the most commonly used additional medications for severe EGPA. This drug, often given as intravenous pulses, interferes with the ability of immune cells to multiply, thereby reducing the body’s inflammatory response. Cyclophosphamide is typically given for about three to six months as initial therapy. After the disease is brought under control with cyclophosphamide, doctors usually switch to a different medication for long-term maintenance to reduce the risk of side effects associated with prolonged cyclophosphamide use.^[10][13]

For maintenance therapy after the initial treatment phase, several medications are available. Azathioprine is a commonly used option that works by blocking certain chemical processes needed for immune cell function. Methotrexate is another maintenance option, taken weekly either as pills or injections, which interferes with cell division and immune responses. Mycophenolate is also used in some cases, working by blocking an enzyme that immune cells need to multiply. The choice among these medications depends on individual patient factors, including other health conditions, potential drug interactions, and previous treatment responses.^[10][14]

The duration of treatment for EGPA is substantial. Most treatment protocols recommend continuing therapy for at least 12 to 18 months, though many people need treatment for even longer periods. Some individuals may require low-dose maintenance therapy indefinitely to prevent disease flares. Regular monitoring is essential throughout treatment to assess disease activity, check organ function, and watch for medication side effects.^[10]

A more recent addition to the standard treatment arsenal is rituximab, a medication originally developed for certain cancers and other autoimmune conditions. Rituximab is a monoclonal antibody that targets and depletes a specific type of immune cell called B lymphocytes. While rituximab is officially approved for other forms of vasculitis (blood vessel inflammation), doctors have found it useful in EGPA, particularly for people who don’t respond well to standard treatments or who experience disease relapses. However, rituximab appears to work better in people who test positive for certain antibodies called ANCA (anti-neutrophil cytoplasmic antibodies) than in those who test negative.^[10][13]

Managing asthma remains a critical part of EGPA treatment, since almost everyone with this condition has asthma as a prominent feature. Asthma treatment in EGPA follows the same stepwise approach used for people with asthma who don’t have vasculitis. This typically includes inhaled medications such as bronchodilators to open airways and inhaled corticosteroids to reduce lung inflammation. The difference is that asthma medications in EGPA must be used alongside the systemic treatments for vasculitis.^[10]

Understanding and Managing Side Effects

The medications used to treat EGPA can cause significant side effects, especially with prolonged use. Corticosteroids, while highly effective, carry numerous potential problems. Weight gain is extremely common, as these drugs increase appetite and cause the body to retain fluid and redistribute fat, particularly to the face, neck, and trunk. High blood sugar is another frequent concern; prednisone can trigger diabetes or worsen existing diabetes by affecting how the body handles glucose. Bone thinning, or osteoporosis, develops over time as corticosteroids interfere with bone formation and increase bone breakdown, raising the risk of fractures.^[14]

Corticosteroids also increase the risk of infections by suppressing the immune system. This means that people taking these medications need to be particularly careful about avoiding sick contacts and should promptly report any signs of infection to their doctors. Eye problems, including cataracts and increased pressure inside the eye (glaucoma), can develop with long-term corticosteroid use, making regular eye examinations important. Mood changes, including anxiety, depression, or even more severe psychiatric symptoms, can occur, particularly with higher doses.^[14]

Cyclophosphamide carries its own set of concerns. This medication can reduce blood cell counts, increasing the risk of infections, bleeding, and anemia. It can affect fertility in both men and women, which is an important consideration for people of childbearing age. Bladder irritation and, in rare cases, bladder cancer can occur with prolonged use. Regular blood tests are necessary to monitor blood cell counts and organ function during cyclophosphamide treatment.^[13]

The maintenance medications also have side effects, though generally less severe than those of cyclophosphamide. Azathioprine can cause nausea, liver enzyme abnormalities, and reduced blood cell counts. Methotrexate may cause mouth sores, nausea, liver problems, and lung inflammation. Mycophenolate commonly causes gastrointestinal symptoms like diarrhea and stomach upset. Regular blood monitoring helps doctors detect these problems early so that doses can be adjusted or medications changed if necessary.^[13]

Emerging Treatments in Clinical Trials

The landscape of EGPA treatment has been evolving rapidly in recent years, with several promising new approaches being tested in clinical trials. Much of this progress stems from a better understanding of how eosinophils are regulated in the body. Scientists have discovered that a substance called interleukin-5 (IL-5) plays a crucial role in the production, survival, and activation of eosinophils. This discovery has led to the development of medications that specifically target IL-5, offering a more precise way to control eosinophil numbers without broadly suppressing the entire immune system.^[9]

Mepolizumab is one such IL-5-targeting medication that has shown substantial promise in EGPA. Mepolizumab is a monoclonal antibody that binds to IL-5 and prevents it from attaching to eosinophils, thereby reducing eosinophil production and survival. This medication is given as a monthly injection under the skin. Clinical trials of mepolizumab in EGPA have demonstrated that it can help people achieve and maintain remission while reducing their need for corticosteroids. The ability to lower corticosteroid doses is particularly valuable given the significant side effects these drugs can cause over time. Mepolizumab has been approved for use in adult patients with EGPA in several countries, representing an important advancement in treatment options.^[10][13]

The clinical trials that led to mepolizumab’s approval were primarily Phase III studies, which are large-scale trials that compare a new treatment against standard care or placebo in hundreds of patients to definitively determine effectiveness and safety. In these trials, mepolizumab was added to standard treatment, and researchers tracked whether patients remained in remission and how much they could reduce their corticosteroid doses. The results showed that significantly more people treated with mepolizumab were able to achieve periods of remission compared to those receiving placebo, and they were able to take lower doses of prednisone.^[13]

Benralizumab is another IL-5 pathway-targeting medication that has been approved for EGPA treatment. Unlike mepolizumab, which blocks IL-5 itself, benralizumab targets the IL-5 receptor on eosinophils. This means it binds to the receiving structure on eosinophil cells rather than to the IL-5 signal itself. This subtle difference in mechanism leads to a more rapid and complete depletion of eosinophils from the bloodstream. Benralizumab is also given by injection under the skin, though typically less frequently than mepolizumab after the initial loading period. Clinical trials have shown that benralizumab can help control EGPA symptoms and reduce corticosteroid requirements, making it another valuable option for people with this condition.^[10]

These IL-5-targeted therapies are particularly useful for maintaining disease control and allowing patients to reduce their corticosteroid doses, which is why they are often called corticosteroid-sparing agents. They are typically considered for people who have relapsing or refractory EGPA (meaning disease that comes back after initial treatment or doesn’t respond well to standard therapy) and for maintaining remission, especially when asthma control is a major concern. Current guidelines suggest these medications are most appropriate for patients without immediately life-threatening or organ-threatening manifestations, as they may not work quickly enough in emergency situations.^[9][10]

Understanding Clinical Trial Phases

Clinical trials progress through several phases, each designed to answer specific questions about a new treatment. Phase I trials are the first studies in humans, typically involving small numbers of participants. The main goal of Phase I is to assess safety—determining what doses can be tolerated, what side effects occur, and how the body processes the medication. Phase I trials for EGPA treatments might enroll 20 to 80 participants and last for several months.^[9]

Phase II trials expand to larger groups, usually involving 100 to 300 participants. These studies focus on determining whether the treatment actually works for the intended purpose and continuing to evaluate safety. In EGPA, Phase II trials might measure outcomes like reduction in eosinophil counts, improvement in disease activity scores, ability to reduce corticosteroid doses, or improvements in specific organ involvement. These trials help researchers understand the optimal dose and schedule for the medication.^[9]

Phase III trials are large, definitive studies that compare the new treatment to current standard care or placebo in hundreds or even thousands of patients. These trials provide the evidence needed for regulatory approval by agencies like the U.S. Food and Drug Administration or the European Medicines Agency. Phase III trials in EGPA typically last for at least one year and assess major outcomes like achieving disease remission, preventing relapses, corticosteroid-sparing effects, and long-term safety.^[9]

Phase IV trials occur after a medication has been approved and is in widespread use. These studies continue to monitor long-term effectiveness, safety, and optimal use patterns in much larger, more diverse populations than were included in earlier trials. Phase IV studies might identify rare side effects that didn’t appear in earlier, smaller trials.^[9]

Other Experimental Approaches

Beyond the IL-5-targeting medications that have already gained approval, researchers are investigating several other therapeutic approaches for EGPA. Some studies are examining whether rituximab can be optimized for use specifically in EGPA, exploring the best dosing schedules and identifying which patients are most likely to benefit. Since rituximab appears more effective in ANCA-positive EGPA, trials are investigating whether ANCA status should guide treatment selection.^[10]

Another medication that has been studied in EGPA is omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), a substance involved in allergic reactions. Since EGPA often occurs in people with severe allergies and asthma, and because the allergic component appears important in the disease, researchers have explored whether omalizumab might help control EGPA. Some studies have shown that omalizumab can have a corticosteroid-sparing effect in people with refractory or relapsing EGPA, though reducing corticosteroid doses too aggressively while on omalizumab may increase the risk of severe disease flares. The role of omalizumab in EGPA continues to be refined through ongoing research.^[10]

Clinical trials for EGPA are conducted at specialized medical centers around the world. In Europe, many trials take place at university hospitals and specialized vasculitis centers with expertise in rare diseases. In the United States, trials are often conducted at academic medical centers, particularly those with dedicated vasculitis or autoimmune disease programs. Clinical trial databases such as ClinicalTrials.gov provide searchable listings of ongoing and planned trials, including information about locations, eligibility criteria, and how to inquire about participation.^[9]

Most Common Treatment Methods

• Corticosteroids
  • Prednisone is the primary medication, typically started at 1 mg/kg/day (maximum 60 mg) and gradually tapered over 12-18 months
  • Intravenous methylprednisolone (1 gram daily for 3 days) is used for severe disease with life-threatening manifestations
  • Works by suppressing immune system activity and reducing eosinophil production and inflammation
  • Side effects include weight gain, high blood sugar, bone loss, increased infection risk, and mood changes
• Immunosuppressive Medications
  • Cyclophosphamide: given intravenously in pulses for 3-6 months for severe disease with organ involvement, then switched to maintenance therapy
  • Azathioprine: used as maintenance therapy after initial disease control
  • Methotrexate: taken weekly as maintenance therapy
  • Mycophenolate: alternative maintenance option for some patients
  • All work by suppressing immune cell activity and reducing inflammation
• Monoclonal Antibody Therapy – Rituximab
  • Targets and depletes B lymphocytes, a type of immune cell
  • Useful for steroid-resistant disease and preventing relapses
  • More effective in ANCA-positive patients than ANCA-negative patients
• Interleukin-5 (IL-5) Antagonists
  • Mepolizumab: monoclonal antibody that blocks IL-5, reducing eosinophil production; given as monthly subcutaneous injection
  • Benralizumab: targets IL-5 receptor on eosinophils, leading to rapid eosinophil depletion; given by subcutaneous injection
  • Both approved for adult EGPA patients to maintain remission and reduce corticosteroid requirements
  • Particularly useful for controlling asthma and as corticosteroid-sparing agents
• Asthma Management
  • Inhaled bronchodilators to open airways
  • Inhaled corticosteroids to reduce lung inflammation
  • Stepwise treatment approach tailored to asthma severity
  • Used alongside systemic EGPA treatments

Treatment Selection and Monitoring

The decision about which treatment approach to use for any given person with EGPA depends on several key factors. Disease severity is paramount—doctors use scoring systems to assess how severe the disease is and which organs are affected. One commonly used tool is the Five Factor Score (FFS), which assigns points based on the presence of specific manifestations such as kidney involvement, heart involvement, gastrointestinal symptoms, and age. A score of zero indicates less severe disease that might be managed with corticosteroids alone, while a score of one or higher suggests more severe disease requiring additional immunosuppressive therapy.^[10]

The presence or absence of ANCA also influences treatment decisions. About 30 to 40 percent of people with EGPA test positive for ANCA, and these individuals tend to have different disease patterns than those who are ANCA-negative. ANCA-positive patients more commonly have kidney involvement and may respond differently to certain treatments, particularly rituximab. ANCA-negative patients more often have heart involvement and may benefit more from IL-5-targeting therapies.^[3][9]

Previous treatment history matters as well. Someone newly diagnosed with EGPA who has never been treated before will receive what’s called “induction therapy” aimed at quickly bringing the disease under control. Someone who has had EGPA for years and is experiencing a relapse might receive “re-induction therapy” that could be similar to or more aggressive than initial treatment, depending on the circumstances. People in remission require “maintenance therapy” designed to keep the disease quiet while minimizing side effects.^[10]

Throughout treatment, regular monitoring is essential to track disease activity, assess treatment response, and detect any problems early. This monitoring includes periodic blood tests to measure eosinophil counts, assess organ function (particularly kidney and liver function), and check for medication side effects. Urinalysis helps detect kidney involvement. Imaging studies such as chest X-rays or CT scans may be used to evaluate lung involvement. Nerve conduction studies can assess peripheral nerve damage. Heart monitoring through electrocardiograms or echocardiograms may be necessary given the risk of cardiac involvement in EGPA.^[9]

The frequency of monitoring varies depending on disease activity and treatment phase. During active disease and initial treatment, appointments and tests might occur every few weeks. Once remission is achieved and maintenance therapy is established, monitoring may occur every few months. However, if symptoms worsen or new problems arise, more frequent monitoring becomes necessary.^[9]

Long-Term Outlook and Disease Management

EGPA is a chronic condition, and while treatment can often bring it under control, relapses are unfortunately common. Relapse rates range from 25 to 49 percent in various studies, meaning that roughly one-quarter to one-half of people experience disease flares after initially achieving remission. This reality means that EGPA requires long-term management and vigilance. Learning to recognize early signs of relapse—such as worsening asthma, new sinus symptoms, skin rashes, numbness or tingling, or general malaise—is important so that treatment can be adjusted promptly.^[10]

The overall prognosis for EGPA has improved dramatically over the decades since the condition was first described. Before effective treatments were available, EGPA could be life-threatening, particularly when it affected the heart, kidneys, or nervous system. With current treatments, most people with EGPA can achieve good disease control and maintain reasonable quality of life, though they may need to continue medications indefinitely. The key to successful outcomes is early diagnosis, appropriate treatment intensity matched to disease severity, careful monitoring, and prompt management of relapses or complications.^[1]

Living with EGPA often requires adapting to a new normal. Fatigue is a common ongoing symptom that many people experience, even when the disease appears controlled on laboratory tests. Physical therapy can help address muscle weakness that may result from nerve involvement or corticosteroid effects. Nutritional attention is important to manage weight gain from corticosteroids and ensure adequate calcium and vitamin D for bone health. Psychological support may be valuable for coping with the emotional challenges of living with a chronic, unpredictable condition.^[20]

Patient support organizations provide valuable resources for people living with EGPA and their families. These groups offer educational materials, connections to others with similar experiences, and advocacy for improved care and research. Organizations such as the Vasculitis Foundation and the American Partnership for Eosinophilic Disorders maintain resources specifically for EGPA and can help patients navigate the challenges of this rare condition.^[5][6]